FEB 20, 2017 10:31 AM PST

New Precious Metal Attacks Cancer Where it Counts

WRITTEN BY: Xuan Pham

Researchers have captured how a new organo-metal compound infiltrates cancer cells and destroys its most vulnerable organelle: the mitochondria.

The organo-metal compound, called FY26, is a rare precious metal known as osmium. It was discovered by scientists at the University of Warwick, who previously reported that the metal seemed to shift the metabolism in ovarian cancer cells. In particular, the metal compound stresses cancer cells to use their defective mitochondria, which is a death sentence for these cells.

"Healthy cells generate their energy in organelles called mitochondria, but cancer cells have defective mitochondria and are forced to generate energy through glycolysis in the cytoplasm. Our new compounds work by attacking the energy balance in cancer cells,” explained Dr. Peter Sadler, a professor a the University of Warwick, and the study’s senior author.

In their latest study, Sadler’s team was able to capture just how FY26 targets cancer cells from the inside. They used X-ray fluorescence to track the compound directly to the mitochondria of cancer cells.

"The advanced nano-focussed x-ray beam at ESRF has not only allowed us to locate the site of action of our novel Organo-Osmium FY26 candidate drug in cancer cells at unprecedented resolution, but also study the movement of natural metals such as zinc and calcium in cells. Such studies open up totally new approaches to drug discovery and treatment,” Dr. Sadler said.

In particular, FY26 is reportedly 49 times more potent than Cisplatin - a common platinum-based chemotherapeutic agent.  "Existing platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin,” said Sadler.

The team also argue that, in addition to the higher potency and selectivity, osmium-based drugs may be cheaper to produce overall. "Cancer drugs with new mechanisms of actions which can combat resistance and have fewer side-effects are urgently needed,” Sadler noted.

Of note, the compound was only tested in ovarian cancer cells and with much higher doses than would be typically used in a clinical setting. As such, further investigations into how FY26 behaves in live animal systems are important to determine if this drug will be appropriate for cancer patients.

Additional sources: MNT

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 07, 2019
Cancer
DEC 07, 2019
Eat more flavonoids!
An apple a day keeps the doctor away? New research published in Nature Communications suggests that there might be some truth to that old saying. But it&rs...
DEC 07, 2019
Genetics & Genomics
DEC 07, 2019
Genetic Cause for Tumor Progression
Researchers from the University of Delaware (UDEL), Harvard Medical School (HMS) and University of California, Los Angeles (UCLA), have discovered a ribonu...
DEC 07, 2019
Cancer
DEC 07, 2019
Can eating mushrooms reduce the risk of prostate cancer?
Now here’s a question: have you eaten your mushrooms yet today? Although mushrooms may not be one of the typically-touted snacks in the healthcare wo...
DEC 07, 2019
Cell & Molecular Biology
DEC 07, 2019
Learning More About the Significant Roles of Tiny Proteins
A microprotein was found to play an important role in relieving cell stress, and may open up new therapeutic avenues for some diseases....
DEC 07, 2019
Cancer
DEC 07, 2019
Understanding H. pylori and gastric cancer
New research published in the journal Gastroenterology offers insight on gastric cancer and the presence of the common bacteria known as H. pylori (Helicob...
DEC 07, 2019
Cancer
DEC 07, 2019
Self-renewing blood stem cells give hope for blood disease treatments
New research details how activating a certain protein may be the key to getting hematopoietic stem cells (HSCs) to self-renew. The research comes from scie...
Loading Comments...